Paclitaxel for breast cancer: The Memorial Sloan-Kettering Cancer Center experience

ONCOLOGY

Volumn 11, Issue 3 SUPPL. 2, 1997, Pages 20-28

  Seidman, Andrew D ^a   Hudis, Clifford A ^a   Raptis, George ^a   Baselga, José ^a   Fennelly, David ^a   Norton, Larry ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EDATREXATE; EPIDERMAL GROWTH FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR; MONOCLONAL ANTIBODY; PACLITAXEL;

BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE II; COMBINED MODALITY THERAPY; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; PACLITAXEL; QUALITY OF LIFE;

EID: 0030996375     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (62)

1. Seidman AD: The emerging role of paclitaxel in breast cancer therapy. Clin Cancer Res 3:247-256, 1995.
2. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol: An active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991.
3. Reichman BS, Seidman AD, Crown JPA, et al: Taxol and recombinant human granulocyte colony stimulating factor as initial therapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993.
4. Seidman AD, Reichman BS, Crown JPA, et al: Paclitaxel as second and subsequent therapy for metastatic breast cancer: Activity independent of prior anthracycline response. J Clin Oncol 13:1152-1159, 1995.
5. Seidman AD, Tiersten A, Hudis C, et al: Phase II trial of paclitaxel by three-hour infusion as salvage chemotherapy for metastatic breast cancer. J Clin Oncol 13:2575-2581, 1995.
6. Seidman AD, Portenoy R, Yao T-J, et al: Quality of life in phase II trials: A study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor. J Natl Cancer Inst 87:1316-1322, 1995.
7. Seidman AD, Weinstock N, Yao T-J, et al: Outcomes assessment among patients receiving chemotherapy for metastatic breast cancer (abstract EL07). Proceedings of the 7th International Congress of Anticancer Treatment, Paris. France, 1997.
8. Zhan Z, Kang Y-K, Regis J, et al: Taxol resistance: In vitro and in vivo studies in breast cancer and lymphoma Proc Am Assoc Cancer Res 34:215, 1993.
9. Lopes NK, Adams EG, Pitts TW, et al: Cell kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242, 1993.
10. Liebmann JE, Cook JA, Lipschultz D, et al: Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines. Br J Cancer 68:1104-1109, 1993.
11. Wilson WH, Berg S, Bryant G, et al: Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: A phase I/II trial of 96 hour infusion. J Clin Oncol 12:1621-1629, 1994.
12. Seidman AD, Hochhauser D, Gollub M, et al: 96 Hour paclitaxel after progression during short taxane exposure: A phase III pharmacokinetic and pharmacodynamic study in metastatic breast cancer. J Clin Oncol 14:1877-1884, 1996.
13. Klaassen U, Wilke I-L, Strumberg D, et al: Phase I study with a weekly 1-h infusion of paclitaxel, in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 32A:547-549, 1996.
14. McCaffrey JA, Seidman AD, Tong W, et al: A phase II and pharmacologic study of Taxol by weekly one-hour infusion in the treatment of patients with metastatic breast cancer (abstract). Breast Cancer Res Treat 41(3):234, 1996.
15. Schmid FA, Sirotnak FM, Otter GM, et al: New folate analogs of the 10-deazaaminoptefin series: Markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice. Cancer Treat Rep 69:551-553, 1985.
16. Vandenberg TA, Pritchard KI, Eisenhauer EA, et al: Phase II study of weekly edatrexate as first-line chemotherapy for metastatic breast cancer: A National Cancer Institute of Canada Clinical Trials Group study. J Clin Oncol 11:1241-1244, 1993.
17. Schornagel JR, van der Vegt S, de Graeff A, et al: Phase II study of edatrexate in chemotherapy-naive patients with metastatic breast cancer. Ann Oncol 3:549-552, 1992.
18. Chou T-C, Otter GM, Sirotnak FM: Schedule-dependent synergism of Taxol or Taxotere with edatrexate against human breast cancer cells in vitro. Cancer Chemother Pharmacol 37:222-228, 1996.
19. Fennelly DM, Rigas JR, Chou D, et al: Phase I trial of edotrexate plus paclitaxel using an administration schedule with demonstrated in vitro synergy. Proc Am Soc Clin Oncol 13:365, 1994.
20. Baselga J, Norton L, Masui R, et al: Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 85:1327-1333, 1993.
21. Baselga J, Norton L, Coplan K, et al: Anti-tumor activity of paclitaxel in combination with anti-growth factor receptor antibodies in breast cancer xenografts. Proc Am Assoc Cancer Res 35-380, 1994.
22. Hudis CA, Seidman AD, Baselga J, et al: Sequential adjuvant therapy with doxorubicin, paclitaxel, and cyclophosphamide for resectable breast cancer involving four or more axillary nodes. Semin Oncol 22(6;suppl 15):18-23, 1995.
23. Hudis C, Seidman A, Raptis G, et al: Sequential paclitaxel (T) -> cyclophosphamide (C) is less toxic than concurrent T+C after dose dense doxorubicin as adjuvant therapy in resected node-positive breast cancer. Proc Am Soc Clin Oncol 15:119, 1996.
24. Roy SN, Horwitz SB: A phosphoglycoprotein associated with Taxol resistance in J774.2 cells. Cancer Res 45:3856-3863, 1985.
25. Kirschener LS, Greenberger LM, Hong Hsu SI, et al: Biochemical and genetic characterization of the multidrug resistant phenotype in murine macrophage-like J774.2 cells. Biochem Pharmacol 43:77-87, 1992.
26. 2 (letter). J Clin Oncol 12:1741-1742, 1994.
27. Capri G, Munzone E, Tarenzi E, et al: Optic nerve disturbances: A new form of paclitaxel neurotoxicity. J Natl Cancer Inst 86:1099-1101, 1994.
28. Schneider JA, Divgi CR, Scott AM, et al: Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer. J Nucl Med 35:1748-1752, 1994.
29. Freilich RJ, Seidman AD, DeAngelis LK, et al: Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel. Cancer 76:232-236, 1995.
30. Kelland LR, Abel G: Comparative in vitro cytotoxicity of Taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30:444-450, 1992.
31. Georgiadis MS, Russell E, Johnson BE, et al: Prolonging the exposure of human lung cancer cell lines to paclitaxel improves the cytotoxicity. Proc AmAssoc Cancer Res 35:341, 1994.
32. Hainsworth JD, Raefsky EL, Thomas K, et al: Paclitaxel administered by 1-hour infusion: Phase I/II study comparing two schedules of administration Proc Am Soc Clin Oncol 14:376, 1995.
33. Loeffler TK, Freund W, Lipke J, et al: Schedule and dose intensified paclitaxel as weekly 1-hour infusion: Evidence for an improved toxicity profile and response activity in pretreated solid tumors. Proc Am Soc Clin Oncol 14:1522, 1995.
34. Fennelly D, Shapiro F, Spriggs D, et al: Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15:187-192, 1997.
35. Klauber N, Parangi S, Flynn E, et al: Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and Taxol. Cancer Res 57:81-86, 1997.
36. Portenoy RK, Thaler H, Kornblith AB, et al: The Memorial Symptom Assessment Scale: An instrument for the evaluation of symptom prevalence, characteristics, and distress. Eur J Cancer 30A:1326-1336, 1994.
37. Schipper H, Clinch J, McMurray A, et al: Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: Development and validation. J Clin Oncol 2:472-483, 1984.
38. Ingham J, Seidman A, Yao T-J, et al: An exploratory study of frequent pain measurement in a cancer clinical trial. Quality of Life Res 5:503-507, 1996.
39. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy Scale-Development and validation of the general measure. J Clin Oncol 11:570-579, 1993.
40. Amadori D, Frassineti GL, Zoli W, et al: A Phase I/II study of paclitaxel and doxorubicin in the treatment of advanced breast cancer Semin Oncol 23(suppl 1):19-23, 1996.
41. Dombernovsky P, Gehl J, Boesgaard M, et al: Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer. Semin Oncol 23(suppl 1):13-18, 1996.
42. Luck H-J, Thomssen C, duBois A, et al: Interim analysis of a phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer. Semin Oncol 23(suppl 1):33-36, 1996.
43. Fisherman J, Cowan KH, Noone M, et al: Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer. J Clin Oncol 14:774-782, 1996.
44. Holmes FA, Valero V, Walters RS, et al: The M. D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. Monogr Natl Cancer Inst 15:161-169, 1993.
45. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699, 1995.
46. Gelmon KA, O'Reilly S, Plederleith IH, et al: Bi-weekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 13:71, 1994.
47. Wasserheit C, Alter R, Speyer J, et al: Phase II trial of paclitaxel and cisplatin in women with metastatic breast cancer. Proc Am Soc Clin Oncol 13:100, 1994.
48. Fennelly D, Gilewski, Hudis C, et al: Phase I trial of sequential edatrexate followed by paclitaxel: A design based on in vitro synergy in patients with advanced breast cancer. Proc Am Soc Clin Oncol 14:101, 1995.
49. Norton L Implications of kinetic heterogeneity in clinical oncology. Semin Oncol 12:231, 1985.
50. Vahdat L, Raptis G, Fennelly D, et al: Rapidly cycled courses of high-dose alkylating agents supported by filgrastim and peripheral blood progenitor cells in patients with metastatic breast cancer. Clin Cancer Res 1:1267-1273, 1995.
51. Fennelly D, Schneider J, Spriggs D, et al: Dose escalation of paclitaxel with high-dose cyclophosphamide, with analysis of progenitor-cell mobilization and hematologic support of advanced ovarian cancer patients receiving rapidly sequenced high-dose carboplatin/cyclophosphamide courses. J Clin Oncol 13:1160-1166, 1995.
52. Mendelsohn J, Baselga J: Antibodies to growth factors and receptors, in De Vita VT, Hellman S, Rosenberg SA (eds): Biologic Therapy of Cancer, pp 607-624. Philadelphia, JB Lippincott, 1995.
53. HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14:737-744, 1996.
54. Fan Z, Baselga J, Masui H, et al: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamine-dichloroplatinum on well established A431 cell xenografts. Cancer Res 53:4637-4642, 1993.
55. Arteaga CL, Dugger TC, Winnier AR: Antiepidermal growth factor receptor (EGFR) monoclonal antibodies sensitize human carcinoma cells to etoposide and restore etoposide sensitivity in drug resistant carcinoma cells in culture. Proc Am Soc Clin Oncol 12:125, 1994.
56. Blagosklonny W, Schulte T, Nguyen P, et al: Taxol-induced apoptosis and phosphorylation of bcl-2 protein involves c-raf-1 and represents a novel c-raf-1 signal transduction pathway. Cancer Res 56:1851-1854, 1997.
57. Tsai C-M, Chang K-T, Wu L-H, et al: Correlations between intrinsic chemoresistance and HER-2//neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res 56:206-209, 1996.
58. Muss HB, Thor AD, Berry DA, et al: C-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 330:1260-1266, 1994.
59. Seidman AD, Baselga J, Yao T-J, et al: HER-2/neu over-expression and clinical taxane sensitivity: A multivariate analysis in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 15:104, 1996.
60. Haldar S, Basu A, Croce CM: Bcl2 is the guardian of microtubule integrity. Cancer Res 57:229-233, 1997.
61. Bonadonna G, Zambetti M, Valagussa P: Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. JAMA 273:542-547, 1995.
62. Hudis C, Lebwohl D, Crown J, et al: Dose intensive sequential crossover adjuvant chemotherapy for women with high risk node positive primary breast cancer, in Salmon S (ed). Adjuvant Therapy of Cancer VII, pp 214-219.